Other contributors to this work include co-first authors Premranjan Kumar, Ob Osahon and David Vides, as well as Nicola Hanania and Charles G
GSH is a necessary cofactor for GPX4 activity
Human evidence, you ask
Disclosures: Sahar Saeed: Novo Nordisk: Consultant, Dana Kablawi: Nothing to Disclose, Tyler Thomas: Nothing to Disclose, Jovana Milic: Nothing to Disclose, Thierry Fotsing Tadjo: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Al Shaima Al Hinai: Nothing to Disclose, Wesal Elgretli: Nothing to Disclose, Claudia Gioe: Nothing to Disclose, Emmanuel Tsochatzis: NovoNordisk: Advisor, Siemens: Advisor, MSD: Advisor, Orphalan: Advisor, Univar: Advisor, Boehringer: Advisor, Echosens: Speaking and Teaching, Orphalan: Speaking and Teaching, Abbvie: Speaking and Teaching, NovoNordisk: Speaking and Teaching, Jemima Finkel: Nothing to Disclose, Luz Ballesteros: Nothing to Disclose, Sanjay Bhagani: Nothing to Disclose, Antonio Cascio: Nothing to Disclose, Giovanni Guaraldi: Nothing to Disclose, Giovanni Mazzola: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support 1091 PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND SEVERE FIBROSIS HAVE WORSE EXECUTIVE FUNCTION PERFORMANCE Ali Weinstein 1 Leyla de Avila 2 Brian Lam 2 Maria Stepanova 2 Jillian Price 2 Carey Escheik 3 Lynn Gerber 2 Zobair Younossi 4 , 1 George Mason University, 2 Beatty Liver/Obesity Research Program, 3 Beatty Liver/ Obesity Research Program, 4 The Global NASH Council Background: Evidence suggests that Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is associated with cognitive dysfunction
